Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Allison

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Gut|July 18, 2023
An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principlesRobert S Bresalier, Carlo Senore, Graeme P Young, et al.
Nature|January 17, 2020
B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.
Mayo Clinic Proceedings|July 28, 2015
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer DrugsAyalew Tefferi, Hagop Kantarjian, S Vincent Rajkumar, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Gut|July 18, 2023
An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principlesRobert S Bresalier, Carlo Senore, Graeme P Young, et al.
Nature|January 17, 2020
B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.
Mayo Clinic Proceedings|July 28, 2015
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer DrugsAyalew Tefferi, Hagop Kantarjian, S Vincent Rajkumar, et al.
Pageof 4